FDA Brief

Warning letters Food

FDA warning letter to

Mercola.com, LLC

High riskIssued Feb 18, 2021Posted Mar 4, 2021Center for Food Safety and Applied Nutrition (CFSAN)

FDA warned Mercola.com that website claims made its vitamin C, D3, and quercetin products unapproved COVID-19 drugs.

What happened

FDA reviewed mercola.com and mercolamarket.com on February 8, 2021, and a Twitter page that directed consumers to mercolamarket.com. FDA found Liposomal Vitamin C, Liposomal Vitamin D3, and Quercetin and Pterostilbene Advanced offered for sale with claims that they mitigate, prevent, treat, diagnose, or cure COVID-19. The claims included statements that high-dose vitamin C kills viruses and that vitamins C and D are useful for COVID-19 prevention and treatment.

What FDA found

  1. FDA says the products are unapproved new drugs because they are sold with claims to mitigate, prevent, treat, diagnose, or cure COVID-19.

    section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a)
  2. FDA says the products are misbranded drugs because their labeling makes misleading drug claims.

    section 502 of the FD&C Act, 21 U.S.C. § 352
  3. FDA says introducing or delivering these products into interstate commerce is prohibited.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)

What FDA wants

FDA tells the company to take immediate action to stop selling these products for COVID-19 and, within 48 hours, email COVID-19-Task-Force-CFSAN@fda.hhs.gov with the specific steps taken, supporting documents, and how it will prevent recurrence; if it cannot complete the actions in 48 hours, it must explain the delay and timetable.

Who should pay attention

  • supplement brands that make health claims online
  • online retailers and social media marketers of vitamin products
  • regulatory teams reviewing COVID-19-related promotional claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk